SUO 2017: Trying to Salvage Problematic Initial Management of Penile Cancer
Washington, DC (UroToday.com) A multidisciplinary panel of penile cancer experts was assembled for the penile cancer session for the 2017 SUO to discuss the importance of multimodal therapy for advanced penile cancer. The panel was moderated by Dr. Viraj Master from Emory University and included Dr. Juanita Crook, a radiation oncologist from the University of British Colombia, Dr. Guru Sonpavde, a medical oncologist from Dana-Farber cancer institute, and Dr. Philippe Spiess, a urologic oncologist from Moffitt Cancer Center. Three cases were discussed, with each of the experts giving their opinion on the optimal treatment course for each patient.
SUO 2017: InPACT Trial - Answering the Unanswered Questions
Washington, DC (UroToday.com) The International penile advanced cancer trial (InPACT) is likely the most important clinical study undertaken to date in the field of advanced penile cancer. Very little high-level evidence currently exists in this space, mainly because of the rarity of the disease. A broad international collaboration was required that harnessed the energy of cooperative groups in Europe and the U.S. to gather enough patients to make a meaningful study. Dr. Curtis Pettaway, the study chair for U.S. clinical sites, presented an overview of the trial and its intended endpoints.
SUO 2017: Penile Cancer – Introduction and Discussion of New 2018 Staging
Washington, DC (UroToday.com) To begin the penile cancer session at the 2017 Society of Urologic Oncology (SUO) meeting, Dr. Viraj Master from Emory University presented the changes in the 8th edition penile cancer staging guidelines. The most significant of these changes are the new definitions of pT2 and pT3 disease.
SUO 2017: When First Line Chemotherapy Fails - Locally Advanced or Metastatic Penile Cancer Patient
Washington, DC (UroToday.com) The survival of patients with metastatic penile cancer remains poor with a median survival of approximately 8 months with best available therapy. Most of the available systemic treatment options are cisplatin based combination with response rates of ranging from 30-35%. Sadly, minimal advances have been made in the last 20 years to improve survival. Dr. Sonpavde, from the Dana Farber Cancer Center, presents the best available evidence of the treatment of patients with metastatic penile cancer and gives insights into future treatment options.